Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
Post-Operative Pain Scores and Analgesic Requirements After Elective Inguinal Herniorrhaphy
|4||Not yet recruiting||
The Application of Negative Atrioventricular Hysteresis in Cardiac Resynchronization Therapy
Letrozole in Assisted Reproductive Technology
† Study has passed its completion date and status has not been verified in more than two years.